Literature DB >> 21328600

Update of uremic toxin research by mass spectrometry.

Toshimitsu Niwa1.   

Abstract

Mass spectrometry (MS) has been successfully applied for the identification and quantification of uremic toxins and uremia-associated modified proteins. This review focuses on the recent progress in the MS analysis of uremic toxins. Uremic toxins include low-molecular weight solutes, protein-bound low-molecular weight solutes, and middle molecules (peptides and proteins). Based on MS analysis of these uremic toxins, the pathogenesis of the uremic symptoms will be elucidated to prevent and manage the symptoms. Notably, protein-bound uremic toxins such as indoxyl sulfate, p-cresyl sulfate, and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid have emerged as important targets of therapeutic removal. Hemodialysis even with a high-flux membrane cannot efficiently remove the protein-bound uremic toxins because of their high albumin-binding property. The accumulation of these protein-bound uremic toxins in the blood of dialysis patients might play an important role in the development of uremic complications such as cardiovascular disease. Indoxyl sulfate is the most promising protein-bound uremic toxin as a biomarker of progress in chronic kidney disease. Novel dialysis techniques or membranes should be developed to efficiently remove these protein-bound uremic toxins for the prevention and management of uremic complications.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328600     DOI: 10.1002/mas.20323

Source DB:  PubMed          Journal:  Mass Spectrom Rev        ISSN: 0277-7037            Impact factor:   10.946


  15 in total

1.  Selectively increasing the clearance of protein-bound uremic solutes.

Authors:  Tammy L Sirich; Frank J-G Luo; Natalie S Plummer; Thomas H Hostetter; Timothy W Meyer
Journal:  Nephrol Dial Transplant       Date:  2012-01-09       Impact factor: 5.992

Review 2.  Metabolomics and renal disease.

Authors:  Eugene P Rhee
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-07       Impact factor: 2.894

3.  Protein-bound P-cresol inhibits human umbilical vein endothelial cell proliferation by inducing cell cycle arrest at G0/G1.

Authors:  Li Li; Jing Li; Xun Li; Fa-Huan Yuan
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 4.  Metabolomics in the study of kidney diseases.

Authors:  Robert H Weiss; Kyoungmi Kim
Journal:  Nat Rev Nephrol       Date:  2011-10-25       Impact factor: 28.314

5.  Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Li Chen; Junhe Shi; Xiaojuan Ma; Dazhuo Shi; Hua Qu
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

6.  Correlation between Serum Levels of Protein-Bound Uremic Toxins in Hemodialysis Patients Measured by LC/MS/MS.

Authors:  Yoshiharu Itoh; Atsuko Ezawa; Kaori Kikuchi; Yoshinari Tsuruta; Toshimitsu Niwa
Journal:  Mass Spectrom (Tokyo)       Date:  2013-04-15

7.  Uremic toxins are conditional danger- or homeostasis-associated molecular patterns.

Authors:  Yu Sun; Candice Johnson; Jun Zhou; Luqiao Wang; Ya-Feng Li; Yifan Lu; Gayani Nanayakkara; Hangfei Fu; Ying Shao; Claudette Sanchez; William Y Yang; Xin Wang; Eric T Choi; Rongshan Li; Hong Wang; Xiao-Feng Yang
Journal:  Front Biosci (Landmark Ed)       Date:  2018-01-01

8.  Metabolites related to gut bacterial metabolism, peroxisome proliferator-activated receptor-alpha activation, and insulin sensitivity are associated with physical function in functionally-limited older adults.

Authors:  Michael S Lustgarten; Lori L Price; Angela Chalé; Roger A Fielding
Journal:  Aging Cell       Date:  2014-07-18       Impact factor: 9.304

9.  An Enlarged Profile of Uremic Solutes.

Authors:  Hisae Tanaka; Tammy L Sirich; Natalie S Plummer; Daniel S Weaver; Timothy W Meyer
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

10.  All-Purpose Containers? Lipid-Binding Protein - Drug Interactions.

Authors:  Tiziana Beringhelli; Elisabetta Gianazza; Daniela Maggioni; Sandra Scanu; Chiara Parravicini; Cristina Sensi; Hugo L Monaco; Ivano Eberini
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.